Trial Profile
A phase I trial of ATA-190-Autologous in multiple sclerosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Nov 2017
Price :
$35
*
At a glance
- Drugs ATA-190 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 09 Nov 2017 According to an Atara Biotherapeutics media release, updated positive results from this trial were presnted at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) in Oct 2017
- 25 Oct 2017 According to an Atara Biotherapeutics media release, this trial was partially funded by MS Research Australia, MS Queensland and Perpetual Foundation.
- 25 Oct 2017 Results (n=10) presented in an Atara Biotherapeutics Media Release.